Article
Oncology
Eun Ju Kim, Jeong Seon Kim, Sieun Lee, Inyoung Cheon, Seo Ree Kim, Yoon Ho Ko, Keunsoo Kang, Xiaochao Tan, Jonathan M. Kurie, Young-Ho Ahn
Summary: The study found that lnc-Nr2f1 is upregulated by ZEB1 and NR2F1 in lung adenocarcinoma cells, and promotes migration and invasion of these cells by regulating TWIST2.
Article
Multidisciplinary Sciences
Tianying Zheng, Wenfei Han, Aijun Wang, Yonggang Wang
Summary: This study reveals that miR-128-3p inhibits epithelial-mesenchymal transition, invasion, and migration of pancreatic cancer cells by targeting ZEB1.
Article
Pharmacology & Pharmacy
Lu Yu, Hyun Ji Kim, Mi Kyung Park, Hyun Jung Byun, Eun Ji Kim, Boram Kim, Minh Tuan Nguyen, Ji Hyun Kim, Gyeoung Jin Kang, Ho Lee, Soo Youl Kim, Seung Bae Rho, Chang Hoon Lee
Summary: This study revealed that Ethacrynic acid (ECA) inhibits the EMT induced by SPC or TGF-β1 in lung cancer cells, potentially through downregulating NDP expression and inhibiting WNT activation. ECA could be a new drug candidate for lung cancer treatment.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Reproductive Biology
Qiao Ping Xu, Kui Deng, Zhen Zhang, Hongkai Shang
Summary: Ovarian cancer is a growing global disease, and there is an urgent need for chemotherapy and targeted therapy. SLFN5 plays an important role in malignancy, but its specific function in ovarian cancer cells is still unclear. This study suggests that SLFN5 expression is related to the progression and malignancy of ovarian cancer, and its silencing has a significant inhibitory effect on the invasion and metastasis ability of ovarian cancer cells. Therefore, SLFN5 may serve as a potential target for future drug development in the treatment of ovarian cancer.
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Medicine, General & Internal
Yan Zhang, Xueting Li, Yingying Gong, Danli Du, Huilei Chen, Lei Liu, Zenong Cheng
Summary: This study aimed to detect the expression of UBE2C, WNT5a, and E-cad in endometrial cancer (EC) and their clinical significance. The results showed that the positive expression of UBE2C and ZEB1 was significantly higher in EC tissues, while the positive expression of WNT5a was significantly lower. Positive expression of UBE2C and ZEB1 was associated with tumor stages, lymph node metastasis, and FIGO stages, while positive expression of E-cad was inversely related. Kaplan-Meier analyses demonstrated that positive expression of UBE2C or ZEB1 was associated with unfavorable overall survival time, while positive expression of WNT5a was associated with favorable overall survival time. Multivariate analysis identified UBE2C, WNT5a, ZEB1, and FIGO stages as independent prognostic factors for EC patients.
Review
Chemistry, Medicinal
Jihye Seo, Jain Ha, Eunjeong Kang, Sayeon Cho
Summary: The complex orchestration of gene expression during the transition of epithelial cells into mesenchymal cells is crucial in cancer development and metastasis. EMT-TFs, as primary regulators of this process, play key roles in metastasis and have been implicated in cancer therapy resistance. This review focuses on three main EMT-TFs - Snail, Twist1, and ZEB1 - and their relationship to drug resistance, as well as possible future approaches targeting EMT-TFs.
ARCHIVES OF PHARMACAL RESEARCH
(2021)
Article
Oncology
Yaoyao Xiong, Xiongbing Zu, Long Wang, Yuan Li, Minfeng Chen, Wei He, Lin Qi
Summary: The study identified lncRNA VIM-AS1 as highly expressed in bladder cancer, especially in metastatic tissues and high-metastatic cell lines. VIM-AS1 acted as a ceRNA for miR-655, competing with ZEB1 for miR-655 binding, promoting EMT in both high- and low-metastatic bladder cancer cells, and enhancing cancer cell metastasis.
CANCER CELL INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Jung-Hwan Park, Minho Moon, Jong-Seok Kim, Sang-Muk Oh
Summary: The study demonstrated that TOPK upregulates EMT and invasion of nonsmall-cell lung cancer cells through HIF-1α/Snail axis and hypoxic signaling. TOPK positively regulates HIF-1α expression, leading to Snail expression, EMT, and invasion of cancer cells. TOPK acts as a critical mediator of hypoxia signaling in nonsmall-cell lung cancer development.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Nongyao Nonpanya, Kittipong Sanookpan, Nicharat Sriratanasak, Chanida Vinayanuwattikun, Duangdao Wichadakul, Boonchoo Sritularak, Pithi Chanvorachote
Summary: Artocarpin targets FAK to suppress EMT and migratory behaviors of lung cancer cells, without affecting normal lung cells.
Article
Integrative & Complementary Medicine
Yih-Shou Hsieh, Shu-Chen Chu, Shih-Chien Huang, Shao-Hsuan Kao, Meng-Shuan Lin, Pei-Ni Chen
Summary: The research showed that gossypol inhibited the invasion and migration of human cervical cancer cells by targeting the FAK signaling pathway and reversing TGF-beta 1-induced EMT.
AMERICAN JOURNAL OF CHINESE MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Claudia M. Garcia-Cuellar, Miguel Santibanez-Andrade, Yolanda I. Chirino, Raul Quintana-Belmares, Rocio Morales-Barcenas, Ericka Marel Quezada-Maldonado, Yesennia Sanchez-Perez
Summary: The study demonstrated that PM10 exposure induces EMT in lung cancer cells, leading to an increase in invasive phenotype. TGFB1 plays a crucial role in this process.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Qiaosi Tang, Ashley Lento, Kensuke Suzuki, Gizem Efe, Tatiana Karakasheva, Apple Long, Veronique Giroux, Mirazul Islam, E. Paul Wileyto, Andres J. Klein-Szanto, Hiroshi Nakagawa, Adam Bass, Anil K. Rustgi
Summary: The study reveals that TP53 mutation is the most common in ESCC, while Rab11-FIP1 gene is significantly downregulated in mutant p53 tumor cells. Genetic knockdown of Rab11-FIP1 results in increased organoid size and promotes tumor cell invasion through mutant p53.
Article
Biotechnology & Applied Microbiology
Aitao Sun, JinBo Li, Weijing Kong, Xiaodong Jiang
Summary: This study investigates the expression and underlying mechanisms of the immunoglobulin superfamily containing leucine-rich repeat (ISLR) in gastric cancer (GC). The findings suggest that ISLR is overexpressed in GC tumor tissues and cells and is associated with lymph node metastasis, tumor size, and clinical stage. Additionally, ISLR regulates the epithelial-mesenchymal transition (EMT) signaling pathway and affects cell viability, proliferation, migration, and invasion in GC cells. These results provide new evidence for the role of ISLR in GC progression.
Article
Biochemistry & Molecular Biology
Qing-Xiang Meng, Ke-Nie Wang, Jun-Hui Li, Hui Zhang, Zhao-Hui Chen, Xue-Jie Zhou, Xu-Chen Cao, Ping Wang, Yue Yu
Summary: The study found that ZNF384 is significantly overexpressed in breast cancer and promotes breast cancer metastasis by regulating ZEB1 expression and inducing an epithelial and mesenchymal-like phenotype. Additionally, ZNF384 may be a target of miR-485-5p, and ZEB1 can up-regulate ZNF384 expression by repressing miR-485-5p expression. These findings provide evidence for the prognostic and therapeutic potential of ZNF384 in breast cancer patients.
MOLECULAR MEDICINE
(2022)
Article
Genetics & Heredity
Narges Maleki, Negar Yavari, Maryam Ebrahimi, Ahmad Faisal Faiz, Roya Khosh Ravesh, Aysan Sharbati, Mohammad Panji, Keivan Lorian, Abdollah Gravand, Mojtaba Abbasi, Omid Abazari, Mehdi Shafiee Mehr, Yasin Eskandari
Summary: Silibinin exhibits strong inhibitory effects on ovarian cancer by suppressing cell viability, migration, and invasion, and promoting apoptosis. It also reverses epithelial-mesenchymal transition mechanism and ameliorates tumor growth.
Meeting Abstract
Oncology
M. Saigi, E. Pros, J. Alburquerque Bejar, I. Catala, S. Verdura, R. Palmero Sanchez, M. Jove, E. Nadal, M. Sanchez-Cespedes
JOURNAL OF THORACIC ONCOLOGY
(2019)
Meeting Abstract
Oncology
M. Sanchez-Cespedes
JOURNAL OF THORACIC ONCOLOGY
(2019)
Meeting Abstract
Oncology
P. Llabata, M. Torres-Diz, A. Gomez, M. Sanchez-Cespedes
JOURNAL OF THORACIC ONCOLOGY
(2019)
Meeting Abstract
Oncology
E. Pros, M. Saigi, J. J. Alburquerque Bejar, M. J. Pajares, B. Martinez-Delgado, J. Carretero, R. Tonda, A. Esteve-Codina, S. Verdura, I. Catala, N. Reguart, O. Juan, E. Nadal, E. Felip, L. Montuenga, M. Sanchez-Cespedes
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Oncology
E. Pros, M. Saigi, D. Alameda, G. Gomez-Mariano, B. Martinez-Delgado, J. J. Alburquerque-Bejar, J. Carretero, R. Tonda, A. Esteve-Codina, I Catala, R. Palmero, M. Jove, C. Lazaro, A. Patino-Garcia, I Gil-Bazo, S. Verdura, A. Teule, J. Torres-Lanzas, D. Sidransky, N. Reguart, R. Pio, O. Juan-Vidal, E. Nadal, E. Felip, L. M. Montuenga, M. Sanchez-Cespedes
ANNALS OF ONCOLOGY
(2020)
Article
Biochemistry & Molecular Biology
M. Carmen Lafita-Navarro, Judit Liano-Pons, Andrea Quintanilla, Ignacio Varela, Rosa Blanco, Fabiana Ourique, Gabriel Bretones, Julia Aresti, Ester Molina, Patrick Carroll, Peter Hurlin, Octavio A. Romero, Montse Sanchez-Cespedes, Robert N. Eisenman, M. Dolores Delgado, Javier Leon
JOURNAL OF BIOLOGICAL CHEMISTRY
(2020)
Article
Oncology
Paula Llabata, Yoichiro Mitsuishi, Peter S. Choi, Diana Cai, Joshua M. Francis, Manuel Torres-Diz, Namrata D. Udeshi, Lior Golomb, Zhong Wu, Jin Zhou, Tanya Svinkina, Estrella Aguilera-Jimenez, Yanli Liu, Steven A. Carr, Montse Sanchez-Cespedes, Matthew Meyerson, Xiaoyang Zhang
MOLECULAR CANCER RESEARCH
(2020)
Article
Oncology
Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedres, Alex Martinez-Marti, Nuria Pardo, Nadia Saoudi-Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M. Mancuso, Paolo Nuciforo, Luis M. Montuenga, Montse Sanchez-Cespedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat
Summary: Immunotherapy has shown unprecedented long-lasting responses in some patients with advanced non-small cell lung cancer (NSCLC). An integrative analysis of genomic and transcriptomic features of long-term immune checkpoint inhibitors (ICIs)-associated responders revealed an association between TMB and benefit to ICIs. High SCNAs burden correlated with poor response, while PD-L1 expression was increased in patients with long-term response. This study suggests that TMB, SCNAs burden, and PD-L1 are complementary determinants of response to ICIs in NSCLC.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Paola Peinado, Alvaro Andrades, Marta Cuadros, Maria Isabel Rodriguez, Isabel E. Coira, Daniel J. Garcia, Juan Carlos Alvarez-Perez, Carlos Balinas-Gavira, Alberto M. Arenas, Juan Rodrigo Patino-Mercau, Juan Sanjuan-Hidalgo, Octavio A. Romero, Luis M. Montuenga, Julian Carretero, Montserrat Sanchez-Cespedes, Pedro P. Medina
Article
Multidisciplinary Sciences
Paula Llabata, Manuel Torres-Diz, Antonio Gomez, Laureano Tomas-Daza, Octavio A. Romero, Joaquim Grego-Bessa, Pere Llinas-Arias, Alfonso Valencia, Manel Esteller, Biola M. Javierre, Xiaoyang Zhang, Montse Sanchez-Cespedes
Summary: MAX mutant SCLCs have either ASCL1 or NEUROD1 or combined characteristics, are MYC independent, and show deficient ncPRC1.6-mediated gene repression.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Octavio A. Romero, Andrea Vilarrubi, Juan J. Alburquerque-Bejar, Antonio Gomez, Alvaro Andrades, Deborah Trastulli, Eva Pros, Fernando Setien, Sara Verdura, Lourdes Farre, Juan F. Martin-Tejera, Paula Llabata, Ana Oaknin, Maria Saigi, Josep M. Piulats, Xavier Matias-Guiu, Pedro P. Medina, August Vidal, Alberto Villanueva, Montse Sanchez-Cespedes
Summary: This study demonstrates the vulnerability of SMARCA4-deficient tumors to histone demethylases KDM6 inhibitors, highlighting a potential therapeutic strategy for treating cancers with SMARCA4 mutations. The research suggests that SMARCA4-mutant tumors have reduced levels of histone demethylases KDM6s and depend heavily on these demethylases for growth, making them susceptible to inhibition.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Elisabet Aliagas, Ania Alay, Maria Martinez-Iniesta, Miguel Hernandez-Madrigal, David Cordero, Mireia Gausachs, Eva Pros, Maria Saigi, Sara Busacca, Annabel J. Sharkley, Alan Dawson, Ramon Palmero, Jose C. Ruffinelli, Susana Padrones, Samantha Aso, Ignacio Escobar, Ricard Ramos, Roger Llatjos, August Vidal, Eduard Dorca, Mar Varela, Montse Sanchez-Cespedes, Dean Fennell, Cristina Munoz-Pinedo, Alberto Villanueva, Xavi Sole, Ernest Nadal
Summary: The study demonstrates that CDK4/6 inhibitors can reduce proliferation of MPM cells by promoting G1 cell cycle arrest and inducing cell senescence. This suggests the potential of using CDK4/6 inhibitors for the treatment of MPM in clinical settings.
BRITISH JOURNAL OF CANCER
(2021)
Review
Oncology
Maria Saigi, Enric Carcereny, Teresa Moran, Marc Cucurull, Ainhoa Hernandez, Eva Pros, Montse Sanchez-Cespedes, Marta Domenech, Anna Martinez-Cardus
Summary: Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic rearrangements, including gene fusions and gene amplification, involving and activating receptor tyrosine kinases (RTKs) are recurrent in solid tumors, particularly in non-small cell lung cancer. Advances in the tools to detect these alterations have deepened our understanding of the underlying biology and tumor characteristics and have prompted the development of novel inhibitors targeting activated RTKs. The review focuses on the genetic and molecular structure of oncogenic RTKs, methods for diagnosis, therapeutic implications of tyrosine kinase inhibitors, and the use of liquid biopsies for monitoring the disease.
CANCER TREATMENT REVIEWS
(2022)
Meeting Abstract
Oncology
Maria Saigi, Ryohei Yoshida, Erik H. Knelson, Navin R. Mahadevan, Amir Vajdi, Israel Canadas, Tran C. Thai, Mark M. Awad, Montse Sanchez-Cespedes, David A. Barbie
Meeting Abstract
Oncology
Juan Jose Alburquerque-Bejar, Maria Saigi, Eva Pros, Octavio Romero, Montse Sanchez-Cespedes